Group One Trading’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-142,300
| Closed | -$18.5K | – | 8000 |
|
|
2025
Q3 | $18.5K | Buy |
142,300
+116,100
| +443% | +$15.9K | ﹤0.01% | 6756 |
|
|
2025
Q2 | $6.28K | Buy |
26,200
+2,500
| +11% | +$667 | ﹤0.01% | 6981 |
|
|
2025
Q1 | $4.67K | Buy |
23,700
+20,700
| +690% | +$10.7K | ﹤0.01% | 6679 |
|
|
2024
Q4 | $1.62K | Sell |
3,000
-32,100
| -91% | -$23.4K | ﹤0.01% | 6788 |
|
|
2024
Q3 | $33.4K | Buy |
35,100
+34,400
| +4,914% | +$39K | ﹤0.01% | 4922 |
|
|
2024
Q2 | $682 | Sell |
700
-125,900
| -99% | -$138K | ﹤0.01% | 6421 |
|
|
2024
Q1 | $200K | Buy |
126,600
+126,400
| +63,200% | +$153K | ﹤0.01% | 3561 |
|
|
2023
Q4 | $159 | Hold |
200
| – | – | ﹤0.01% | 7174 |
|
|
2023
Q3 | $156 | Sell |
200
-20,400
| -99% | -$17.1K | ﹤0.01% | 7444 |
|
|
2023
Q2 | $19.1K | Buy |
+20,600
| New | +$24.6K | ﹤0.01% | 6020 |
|
|
2023
Q1 | – | Sell |
-43,200
| Closed | -$63.1K | – | 7121 |
|
|
2022
Q4 | $63.1K | Sell |
43,200
-6,800
| -14% | -$11K | ﹤0.01% | 4817 |
|
|
2022
Q3 | $54K | Sell |
50,000
-14,300
| -22% | -$26.3K | ﹤0.01% | 5338 |
|
|
2022
Q2 | $109K | Buy |
64,300
+2,600
| +4% | +$4.47K | ﹤0.01% | 4906 |
|
|
2022
Q1 | $127K | Sell |
61,700
-61,500
| -50% | -$166K | ﹤0.01% | 5261 |
|
|
2021
Q4 | $462K | Buy |
123,200
+32,600
| +36% | +$148K | ﹤0.01% | 4220 |
|
|
2021
Q3 | $468K | Buy |
90,600
+68,300
| +306% | +$306K | ﹤0.01% | 4265 |
|
|
2021
Q2 | $95K | Buy |
22,300
+13,400
| +151% | +$65K | ﹤0.01% | 6013 |
|
|
2021
Q1 | $47K | Buy |
8,900
+7,000
| +368% | +$40.1K | ﹤0.01% | 6259 |
|
|
2020
Q4 | $10K | Sell |
1,900
-5,200
| -73% | -$28.3K | ﹤0.01% | 5772 |
|
|
2020
Q3 | $57K | Sell |
7,100
-25,900
| -78% | -$227K | ﹤0.01% | 4555 |
|
|
2020
Q2 | $330K | Sell |
33,000
-5,100
| -13% | -$32K | ﹤0.01% | 2957 |
|
|
2020
Q1 | $104K | Buy |
+38,100
| New | +$126K | ﹤0.01% | 3263 |
|
|
2019
Q4 | – | Sell |
-19,000
| Closed | -$29K | – | 5048 |
|
|
2019
Q3 | $29K | Sell |
19,000
-2,100
| -10% | -$4.91K | ﹤0.01% | 4212 |
|
|
2019
Q2 | $85K | Buy |
+21,100
| New | +$86K | ﹤0.01% | 3473 |
|
|
2019
Q1 | – | Sell |
-35,900
| Closed | -$206K | – | 4723 |
|
|
2018
Q4 | $206K | Buy |
35,900
+35,700
| +17,850% | +$263K | ﹤0.01% | 2663 |
|
|
2018
Q3 | $3K | Sell |
200
-7,400
| -97% | -$77.6K | ﹤0.01% | 4940 |
|
|
2018
Q2 | $90K | Buy |
7,600
+5,600
| +280% | +$69.8K | ﹤0.01% | 3625 |
|
|
2018
Q1 | $22K | Buy |
+2,000
| New | +$17.5K | ﹤0.01% | 4042 |
|
|
2017
Q3 | – | Sell |
-200
| Closed | -$1K | – | 4762 |
|
|
2017
Q2 | $1K | Buy |
+200
| New | +$1.04K | ﹤0.01% | 4618 |
|
Other funds holding ADAP
JAIC
EF
RG
XT
Group One Trading's ADAP Position: Q4 2025 in Review
Group One Trading sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 61,730 shares — an estimated $8.03K sold.
Group One Trading first reported a position in ADAP in Q3 2016 and held it in 27 quarters. The position peaked at $287K in Q2 2020. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.
- Group One Trading reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
- Group One Trading sold 61,730 Adaptimmune Therapeutics shares in Q4 2025, an estimated $8.03K.
- Group One Trading first reported a position in Adaptimmune Therapeutics in Q3 2016 and held it in 27 quarters.
- Group One Trading's Adaptimmune Therapeutics position peaked at $287K in Q2 2020.
- 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.
Based on Group One Trading's 13F filing for Q4 2025, filed 12 Feb 2026.